https://novapharmanews.com/apac/news/regulatory-round-up-drug-approvals-18-may-2026 2026-05-27T04:39:59.140Z NovaPharmaNews en-AU 2026-05-27T04:39:16.935Z Regulatory Round-Up: Drug Approvals on 26 May 2026 https://novapharmanews.com/uploads/articles/regulatory-round-up-drug-approvals-26-may-2026.webp Regulatory Round-Up: Drug Approvals on 26 May 2026 https://novapharmanews.com/apac/news/lundbeck-korean-approval-vyepti-oncology-migraine 2026-05-27T04:45:19.713Z NovaPharmaNews en-AU 2026-05-27T04:39:09.399Z Lundbeck Secures Korean Approval for Vyepti: Implications for Oncology and Migraine Treatment Vyepti, oncology, migraine https://novapharmanews.com/uploads/articles/lundbeck-korean-approval-vyepti-oncology-migraine.webp Lundbeck Secures Korean Approval for Vyepti: Implications for Oncology and Migraine Treatment https://novapharmanews.com/eu/news/maat-pharma-q1-2026-business-update 2026-05-27T04:44:21.602Z NovaPharmaNews en-GB 2026-05-27T04:39:09.399Z MaaT Pharma Q1 2026 Business Update and Financial Results https://novapharmanews.com/uploads/articles/maat-pharma-q1-2026-business-update.webp MaaT Pharma Q1 2026 Business Update and Financial Results https://novapharmanews.com/eu/news/arrowhead-pharmaceuticals-positive-cardiometabolic-data-european-a 2026-05-27T04:44:18.875Z NovaPharmaNews en-GB 2026-05-27T04:39:09.399Z Arrowhead Pharmaceuticals Unveils Positive Cardiometabolic Data at European A cardiometabolic disorders https://novapharmanews.com/uploads/articles/arrowhead-pharmaceuticals-positive-cardiometabolic-data-european-a.webp Arrowhead Pharmaceuticals Unveils Positive Cardiometabolic Data at European A https://novapharmanews.com/apac/news/60-degrees-pharmaceuticals-tafenoquine-clinical-trial-babesiosis 2026-05-27T04:44:22.131Z NovaPharmaNews en-AU 2026-05-27T04:39:09.399Z 60 Degrees Pharmaceuticals Initiates Clinical Trial for Tafenoquine in Babesiosis Patients Tafenoquine, Babesiosis https://novapharmanews.com/uploads/articles/60-degrees-pharmaceuticals-tafenoquine-clinical-trial-babesiosis.webp 60 Degrees Pharmaceuticals Initiates Clinical Trial for Tafenoquine in Babesiosis Patients https://novapharmanews.com/apac/news/bukwang-pharmaceutical-dreamcis-aws-clinical-trials 2026-05-27T04:44:03.047Z NovaPharmaNews en-AU 2026-05-27T04:39:09.399Z Bukwang Pharmaceutical Partners with DreamCIS and AWS for Clinical Trials https://novapharmanews.com/uploads/articles/bukwang-pharmaceutical-dreamcis-aws-clinical-trials.webp Bukwang Pharmaceutical Partners with DreamCIS and AWS for Clinical Trials https://novapharmanews.com/us/news/fda-vs-ema-camizestrant-controversy 2026-05-27T04:44:01.809Z NovaPharmaNews en-US 2026-05-27T04:39:09.399Z FDA vs EMA: The Camizestrant Controversy Camizestrant, oncology https://novapharmanews.com/uploads/articles/fda-vs-ema-camizestrant-controversy.webp FDA vs EMA: The Camizestrant Controversy https://novapharmanews.com/eu/news/critical-medicines-act-impact-pharmaceutical-manufacturing-europe 2026-05-27T04:44:10.190Z NovaPharmaNews en-GB 2026-05-27T04:39:09.399Z The Critical Medicines Act: Transforming Pharma Manufacturing in Europe https://novapharmanews.com/uploads/articles/critical-medicines-act-impact-pharmaceutical-manufacturing-europe.webp The Critical Medicines Act: Transforming Pharma Manufacturing in Europe https://novapharmanews.com/us/news/astellas-xtandi-patent-cliff-strategic-moves 2026-05-27T04:44:14.377Z NovaPharmaNews en-US 2026-05-27T04:39:09.399Z Astellas Faces Xtandi Patent Cliff: Strategic Moves Ahead Xtandi https://novapharmanews.com/uploads/articles/astellas-xtandi-patent-cliff-strategic-moves.webp Astellas Faces Xtandi Patent Cliff: Strategic Moves Ahead https://novapharmanews.com/us/news/best-biotech-stocks-may-2026-clinical-trials 2026-05-27T04:44:17.890Z NovaPharmaNews en-US 2026-05-27T04:39:09.399Z Top Biotech Stocks to Watch in May 2026: Clinical Trials Insights https://novapharmanews.com/uploads/articles/best-biotech-stocks-may-2026-clinical-trials.webp Top Biotech Stocks to Watch in May 2026: Clinical Trials Insights https://novapharmanews.com/eu/news/esmo-breast-cancer-congress-2026-highlights 2026-05-27T04:19:41.191Z NovaPharmaNews en-GB 2026-05-26T10:17:57.034Z ESMO Breast Cancer Congress 2026: Key Insights for Investors oncology, breast cancer https://novapharmanews.com/uploads/articles/esmo-breast-cancer-congress-2026-highlights.webp ESMO Breast Cancer Congress 2026: Key Insights for Investors https://novapharmanews.com/us/news/fda-new-form-483-response-guidance 2026-05-27T04:19:39.255Z NovaPharmaNews en-US 2026-05-26T10:17:57.034Z FDA's New Form 483 Response Guidance: Implications for Pharma https://novapharmanews.com/uploads/articles/fda-new-form-483-response-guidance.webp FDA's New Form 483 Response Guidance: Implications for Pharma https://novapharmanews.com/apac/news/clinical-trials-day-2026-oncology-study-growth 2026-05-27T04:19:59.193Z NovaPharmaNews en-AU 2026-05-25T21:27:42.045Z Clinical Trials Day 2026: Oncology Study Growth Insights oncology https://novapharmanews.com/uploads/articles/clinical-trials-day-2026-oncology-study-growth.webp Clinical Trials Day 2026: Oncology Study Growth Insights https://novapharmanews.com/us/news/liminatus-pharma-innocsai-merger-market-analysis 2026-05-27T04:20:05.193Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z Liminatus Pharma to Merge with InnocsAI: A Market Analysis https://novapharmanews.com/uploads/articles/liminatus-pharma-innocsai-merger-market-analysis.webp Liminatus Pharma to Merge with InnocsAI: A Market Analysis https://novapharmanews.com/us/news/biomarin-swot-analysis-rare-disease-competitive-headwinds 2026-05-27T04:20:01.244Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z BioMarin's SWOT Analysis: Competitive Challenges Ahead rare disease https://novapharmanews.com/uploads/articles/biomarin-swot-analysis-competitive-challenges.webp BioMarin's SWOT Analysis: Competitive Challenges Ahead https://novapharmanews.com/apac/news/health-news-round-up-immunotherapy-pcos-clopidogrel-trials 2026-05-27T04:19:43.223Z NovaPharmaNews en-AU 2026-05-25T21:27:42.045Z Health News Round-Up: Immunotherapy, PCOS, and Clopidogrel Trials clopidogrel, depression, PCOS https://novapharmanews.com/uploads/articles/health-news-round-up-immunotherapy-pcos-clopidogrel-trials.webp Health News Round-Up: Immunotherapy, PCOS, and Clopidogrel Trials https://novapharmanews.com/eu/news/mayer-brown-serb-pharmaceuticals-idefirix-acquisition 2026-05-27T04:19:45.184Z NovaPharmaNews en-GB 2026-05-25T21:27:42.045Z Mayer Brown Advises SERB Pharmaceuticals on Idefirix® Acquisition imlifidase, Idefirix https://novapharmanews.com/uploads/articles/mayer-brown-serb-pharmaceuticals-idefirix-acquisition.webp Mayer Brown Advises SERB Pharmaceuticals on Idefirix® Acquisition https://novapharmanews.com/eu/news/ireland-clinical-trials-eu-comparison 2026-05-27T04:19:47.186Z NovaPharmaNews en-GB 2026-05-25T21:27:42.045Z Ireland's Clinical Trials: A Comparative Analysis with EU Peers https://novapharmanews.com/uploads/articles/ireland-clinical-trials-eu-comparison.webp Ireland's Clinical Trials: A Comparative Analysis with EU Peers https://novapharmanews.com/eu/news/chmp-may-2026-output-shift-european-drug-development 2026-05-27T04:19:49.222Z NovaPharmaNews en-GB 2026-05-25T21:27:42.045Z CHMP May 2026 Output: A Shift in European Drug Development https://novapharmanews.com/uploads/articles/chmp-may-2026-output-shift-european-drug-development.webp CHMP May 2026 Output: A Shift in European Drug Development https://novapharmanews.com/us/news/fda-approves-datopotamab-deruxtecan-dlnk-metastatic-tnbc 2026-05-27T04:19:51.225Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z FDA Approves Datopotamab deruxtecan-dlnk for Metastatic TNBC Datopotamab deruxtecan-dlnk, oncology, metastatic TNBC https://novapharmanews.com/uploads/articles/fda-approves-datopotamab-deruxtecan-dlnk-metastatic-tnbc.webp FDA Approves Datopotamab deruxtecan-dlnk for Metastatic TNBC https://novapharmanews.com/eu/news/ema-approves-novo-wegovy-weight-loss-drug 2026-05-27T04:19:53.190Z NovaPharmaNews en-GB 2026-05-25T21:27:42.045Z EMA Approves Novo's Wegovy: A Game Changer in Weight Loss semaglutide, Wegovy, weight loss https://novapharmanews.com/uploads/articles/ema-approves-novo-wegovy-weight-loss-drug.webp EMA Approves Novo's Wegovy: A Game Changer in Weight Loss https://novapharmanews.com/us/news/fda-drug-approval-decisions-may-2026 2026-05-27T04:21:43.800Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z FDA Drug Approval Decisions Expected in May 2026: What to Anticipate https://novapharmanews.com/uploads/articles/fda-drug-approval-decisions-may-2026.webp FDA Drug Approval Decisions Expected in May 2026: What to Anticipate https://novapharmanews.com/apac/news/datroway-approved-metastatic-tnbc 2026-05-27T04:19:59.501Z NovaPharmaNews en-AU 2026-05-25T21:27:42.045Z Datroway Approved: A New Hope for Metastatic TNBC Patients Datroway, oncology, breast cancer, metastatic triple-negative breast cancer https://novapharmanews.com/uploads/articles/datroway-approved-metastatic-tnbc.webp Datroway Approved: A New Hope for Metastatic TNBC Patients https://novapharmanews.com/us/news/aurobindo-pharma-oai-classification-drug-approvals 2026-05-27T04:20:03.229Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z Aurobindo Pharma's OAI Classification: Implications for Drug Approvals https://novapharmanews.com/uploads/articles/aurobindo-pharma-oai-classification-drug-approvals.webp Aurobindo Pharma's OAI Classification: Implications for Drug Approvals